NCT01982955 2022-11-08
Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)
Merck KGaA, Darmstadt, Germany
Phase 1/2 Completed
Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany